A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

PURPOSE: Oral administration of the alkylating agent cyclophosphamide at low doses, metronomic dosing, is well tolerated, with efficacy in multiple tumor types. Poly(ADP-ribose) polymerase (PARP) inhibition potentiates effects of cyclophosphamide in preclinical models. We conducted a phase I trial o...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kummar, Shivaani, Ji, Jiuping, Morgan, Robert, Lenz, Heinz-Josef, Puhalla, Shannon L., Belani, Chandra P., Gandara, David R., Allen, Deborah, Kiesel, Brian, Beumer, Jan H., Newman, Edward M., Rubinstein, Larry, Chen, Alice, Zhang, Yiping, Wang, Lihua, Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306481/
https://ncbi.nlm.nih.gov/pubmed/22307137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-2821
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg